Arca
Skip to content
Tools
Tools

HDAC1: Histone deacetylase 1

Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on HDAC1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Vorinostat

Phase 30

    Phase 21

    • Mocetinostat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      VorinostatApprovedMerck & Co. (MSD)Small moleculeInhibitorHistone deacetylase 1 inhibitor28
      MocetinostatPhase 2Mirati Therapeutics Inc.Small moleculeInhibitorHistone deacetylase 1 inhibitor2

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabVorinostatPhase 2Not yet recruitingNew Approaches to Neuroblastoma Therapy ConsortiumDec 3, 2025
      An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.Sep 2, 2025
      Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.Sep 2, 2025
      Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) PopulationVorinostatPhase 2RecruitingSung Won ChoiMay 29, 2025
      A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]VorinostatEarly phase 1RecruitingUniversity of MinnesotaNov 18, 2024
      Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerVorinostatPhase 2RecruitingFred Hutchinson Cancer CenterNov 24, 2023
      TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIVorinostatPhase 1 / Phase 2RecruitingTanja Andrea GruberMay 8, 2023
      Venetoclax to Augment Epigenetic Modification and ChemotherapyVorinostatPhase 1RecruitingMedical College of WisconsinApr 7, 2022
      Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaMocetinostatPhase 1Active, not recruitingJonsson Comprehensive Cancer CenterMar 6, 2020
      Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.MocetinostatPhase 1Active, not recruitingMemorial Sloan Kettering Cancer CenterJul 18, 2017

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Neoplasm
      0.57
      Primary cutaneous T-cell non-Hodgkin lymphoma
      0.57
      Plasma cell myeloma
      0.57
      T-cell non-Hodgkin lymphoma
      0.52
      Peripheral T-cell lymphoma, not otherwise specified
      0.52
      Mature T-cell and NK-cell non-Hodgkin lymphoma
      0.51
      Cancer
      0.50

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      HDAC1

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL325, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q13547, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.